Pharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
About This Group of Stocks
Our Expert Thinking
Pharmaceutical companies offer a unique combination of stability and growth potential. With consistent demand for healthcare and ongoing innovation in treatments, this industry is projected to grow at 7% annually, reaching $1.9 trillion by 2027.
What You Need to Know
These pharma stocks represent companies focused on developing life-improving and life-saving medications. The healthcare sector tends to be more resilient during economic downturns, as medical needs remain constant regardless of market conditions.
Why These Stocks
This collection includes established pharmaceutical giants alongside innovative biotech companies. These stocks were selected based on their market leadership, research capabilities, and potential for growth through new treatments and medications.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Unlock all stocks by downloading the app for FREE.
It only takes 60 seconds.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+43.86%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 43.86% over the next year.
Stocks Rated Buy by Analysts
15 of 23 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Healthcare's Golden Opportunity
The pharma industry is expected to reach $1.9 trillion by 2027. Getting in now means you could benefit from this massive growth trajectory as companies develop new treatments.
Innovation Worth Watching
Companies like Moderna and Novavax showed how pharmaceutical breakthroughs can lead to extraordinary gains. These stocks represent the future of healthcare innovation.
Recession-Resistant Potential
Healthcare needs remain constant regardless of economic conditions, making pharma stocks potentially more stable during market downturns while still offering growth.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Unlock all the stocks in this group on Nemo
Sign up free to view all assets in this group and never miss out on another investment opportunity with Nemo.
Sign up in 60 seconds
Zero commission trading
SIPC-protected up to $500,000
Backed by Exinity Group
6% AER interest on uninvested cash, paid out daily
AI investment insights
Discover More Opportunities
American Manufacturing's $550B Boost
A new trade agreement between the U.S. and Japan establishes a 15% tariff on Japanese imports and secures a $550 billion investment in American industries. This deal creates a growth opportunity for domestic manufacturers and automotive suppliers set to benefit from the major industrial investment.
UK Challenges Mobile's Duopoly
The United Kingdom is increasing its antitrust scrutiny on Apple and Google's dominant mobile platforms. This regulatory pressure could create a more competitive landscape, benefiting independent app developers and companies offering alternative mobile services.
Telecom's New Bundle Play
T-Mobile's strong subscriber growth, fueled by premium plans with bundled streaming, signals a major shift in the telecommunications industry. This creates an investment opportunity focused on companies at the forefront of the convergence between connectivity and content.
Frequently Asked Questions
Everything you need to know about the product and billing.
See the full stock group
Download Nemo to see all stocks in this group